Methods and Compositions for Modulating Peripheral Immune Function
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 13/441,311, filed Apr 6, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,655,927 | Methods and Compositions for Modulating Peripheral Immune Function In force · High confidence | Sanbio, Inc. | In force | High confidence | ||
| US 10,543,234 | Methods and Compositions for Modulating Peripheral Immune Function In force · High confidence | Sanbio, Inc. | In force | High confidence | ||
| US RE46,382 | Methods and Compositions for Modulating Peripheral Immune Function In force · Low confidence | Sanbio, Inc. | In force | Low confidence | ||
| US 11,903,972 | Methods and Compositions for Modulating Peripheral Immune Function In force · Medium confidence | Sanbio, Inc. | In force | Medium confidence | ||
| US 8,785,190 | Methods and Compositions for Modulating Peripheral Immune Function Surrendered on reissue May 2, 2017 Surrendered on reissue May 2, 2017 · Medium confidence | Sanbio, Inc. | Surrendered on reissue May 2, 2017 | Surrendered on reissue May 2, 2017 | Medium confidence | |
| Application 18/408,002 | Methods and Compositions for Modulating Peripheral Immune Function Pending Not granted | Sanbio, Inc. | Pending | Not granted |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Sanbio, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.